Crossmark

Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study

Crossref DOI link: https://doi.org/10.1007/s00408-021-00436-8

Published Online: 2021-04-07

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Friedman, Marcia A. https://orcid.org/0000-0001-6722-2159
Le, Brian

Stevens, Janelle

Desmarais, Julianna

Seifer, Daniel

Ogle, Kimberly

Choi, Dongseok

Harrington, Christina A.

Jackson, Peter

Rosenbaum, James T.
Funding

Funding for this research was provided by:

Pfizer Pharmaceuticals

National Eye Institute (RO1 EY020249)

National Eye Institute (RO1 EY026572)

National Eye Institute (P30 EY010572)

National Center for Advancing Translational Sciences (KL2TR002370)

National Heart, Lung, and Blood Institute (3T32HL094294-08S1)

Research to Prevent Blindness (Unrestricted Grant)

Grandmaison Fund for Autoimmunity Research

William and Mary Bauman Foundation

Stan and Madelle Rosenfeld Family Trust

School of Medicine, Oregon Health and Science University (Wheels Up)
License Information

Text and Data Mining valid from 2021-04-01

Version of Record valid from 2021-04-01
More Information

Article History

Received: 22 December 2020

Accepted: 4 March 2021

First Online: 7 April 2021

Declarations

:

: JTR consults for Gilead, Abbvie, UCB, Roche, Santen, Corvus, Celldex, Affibody, Keyverna, Horizon, and Novartis.

: This study was approved by the Oregon Health & Science University institutional review board (IRB 00017902) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

: Informed consent was obtained from all individual participants included in the study.

: Participants provided informed consent for publication of this study.

Document is current

Any future updates will be listed below